HDL and LDL as therapeutic targets for cardiovascular disease prevention: The possible role of niacin

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 8, 2010, Pages 553-557

  Olsson, A G ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AZETIDINE DERIVATIVE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID;

BLOOD; CARDIOVASCULAR DISEASE; HUMAN; SHORT SURVEY;

ANTICHOLESTEREMIC AGENTS; AZETIDINES; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; NIACIN;

EID: 77956746999     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.07.003     Document Type: Short Survey

References (23)

1. CDP Research Group Clofibrate and niacin in coronary heart disease. JAMA 1975, 231:360-381.
2. Canner P., Berge K., Wenger N., Stamler J., Friedman L., Prineas R., et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
3. Carlson L., Rosenhamer G. Reduction of mortality in the Stockholm ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223(5):405-418.
4. Brown B.G., Zhao X.-Q., Chait A., Fisher L.D., Cheung M.C., Morse J.S., et al. Simvastatin and niacin, Antioxidant Vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345(22):1583-1592.
5. Taylor A.J., Villines T.C., Stanek E.J., Devine P.J., Griffen L., Miller M., et al. Extended-Release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22):2113-2122.
6. Lee J.M.S., Robson M.D., Yu L.-M., Shirodaria C.C., Cunnington C., Kylintireas I., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and Vascular Function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009, 54(19):1787-1794.
7. Blumenthal R.S., Michos E.D. The HALTS trial - Halting atherosclerosis or Halted Too early?. N Engl J Med 2009, 361(22):2178-2180.
8. Kastelein J.J.P., Bots M.L. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med 2009, 361(22):2180-2183.
9. Carlson L. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005, 258(2):94-114.
10. Crouse J., Raichlen J., Riley W., Evans G., Palmer M., O'Leary D., et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007, 297(12):1344-1353.
11. Rossebo A.B., Pedersen T.R., Boman K., Brudi P., Chambers J.B., Egstrup K., et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008, 359(13):1343-1356.
12. Finn A.V., Kolodgie F.D., Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol February 1, 2010, 30(2):177-181.
13. Coronary Drug Project report on clofibrate and niacin. Atherosclerosis 1978, 30(3):239-240.
14. Benyó Z., Gille A., Kero J., Csiky M., Suchánková M.C., Nusing R.M., et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acidinduced flushing. J Clin Invest 2005, 115(12):3634-3640.
15. Cheng K, Wu T-J, Wu KK, Sturino C, Metters K, Gottesdiener K, et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. 2006 April 25, 2006;103(17):6682-7.
16. Morrow J.D., Awad J.A., Oates J.A., Roberts L.J. Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans. J Invest Dermatol 1992 May, 98(5):812-815.
17. Paolini J., Bays H., Ballantyne C., Davidson M., Pasternak R., Maccubbin D., et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol Clin 2008, 26(4):547-560.
18. Maccubbin D., Bays H.E., Olsson A.G., Elinoff V., Elis A., Mitchel Y., et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008, 62(12):1959-1970.
19. Norquist J.M., Watson D.J., Yu Q., Paolini J.F., McQuarrie K., Santanello N.C. Validation of a questionnaire to assess niacin-induced cutaneous flushing. Curr Med Res Opin 2007, 23(7):1549-1560.
20. Kaijser L., Eklund B., Olsson A., Carlson L. Dissociation of the effects of nicotinic acid on vasodilatation and lipolysis by a prostaglandin synthesis inhibitor, indomethacin, in man. Med Biol 1979, 57(2):114-117.
21. HPS2-THRIVE: Treatment of High density lipoprotein to Reduce the Incidence of Vascular Events [database on the Internet]. 2008.
22. Cannon C.P., Giugliano R.P., Blazing M.A., Harrington R.A., Peterson J.L., Sisk C.M., et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: vytorin Efficacy International Trial): Comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J 2008, 156(5):826-832.
23. Califf R.M., Lokhnygina Y., Cannon C.P., Stepanavage M.E., McCabe C.H., Musliner T.A., et al. An update on the improved reduction of outcomes: vytorin efficacy International Trial (IMPROVE-IT) design. Am Heart J 2010, 159(5):705-709.